BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway

Reuters
Sep 15
BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular <a href="https://laohu8.com/S/AMD">AMD</a> With Multiple Ascending Dose Enrollment Underway

Sept 15 (Reuters) - Kalaris Therapeutics Inc KLRS.O:

  • KALARIS THERAPEUTICS NOW ENROLLING PHASE 1B/2 MULTIPLE ASCENDING DOSE STUDY OF TH103 IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  • KALARIS THERAPEUTICS INC - PHASE 1B/2 DATA EXPECTED IN 2H 2026

Source text: ID:nGNX7pwVn5

Further company coverage: KLRS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10